Angela M. Fulgenzi

Du Cane Road
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 35 publications

Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 28, 2025

A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.

A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab plus bevacizumab in hepatocellular carcinoma.

Journal: Journal of hepatology

Published: September 04, 2025

ctDNA: A Gateway for Personalized Risk Stratification in Surgically Resectable Hepatocellular Cancer.

ctDNA: A Gateway for Personalized Risk Stratification in Surgically Resectable Hepatocellular Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 03, 2024

The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study.

The use of advanced machine learning to predict outcomes after atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: a retrospective cohort study.

Journal: The Lancet. Digital health

Published: October 01, 2024

Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence.

Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence.

Journal: JHEP reports : innovation in hepatology

Published: August 05, 2024

Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction.

Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction.

Journal: JAMA oncology

Published: July 18, 2024

Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis.

Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis.

Journal: The Lancet. Oncology

Published: May 08, 2024

ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab.

ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab.

Journal: Journal of hepatocellular carcinoma

Published: February 03, 2024

Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.

Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment.

Journal: Hepatology (Baltimore, Md.)

Published: January 29, 2024

Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study.

Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 18, 2024

A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma.

A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma.

Journal: JHEP reports : innovation in hepatology

Published: September 19, 2023

Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival.

Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival.

Journal: Cancers

Published: September 18, 2023

Showing 1-12 of 35

Last Updated: 09/26/2026